{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-24-000117","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.073688+00:00","generated_at":"2026-05-31T13:45:08.709830+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Agios Q2 2024 net loss $96.1M; PYRUKYND rev $8.6M; plans thalassemia sNDA by year-end","bullets":["PYRUKYND net revenue $8.6M in Q2 2024, up 5% sequentially; 128 patients on therapy.","Net loss $96.1M vs $83.8M YoY; cash, equivalents, marketable securities $645.3M at June 30.","Phase 3 ENERGIZE-T met primary endpoint in transfusion-dependent thalassemia; sNDA filing planned by end of 2024.","Announced $905M purchase agreement with Royalty Pharma for vorasidenib royalty; total $1.1B payable upon FDA approval.","Announced ACTIVATE-KidsT topline data in pediatric PK deficiency; ACTIVATE-Kids enrollment complete, data in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-24-000117","json":"https://secwatch.observer/filing/0001439222-24-000117.json","markdown":"https://secwatch.observer/filing/0001439222-24-000117.md","text":"https://secwatch.observer/filing/0001439222-24-000117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000117/0001439222-24-000117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000117/agio-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:45:08.709830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}